| Literature DB >> 17934070 |
Unn-Merete Fagerli1, Randi U Holt, Toril Holien, Thea K Vaatsveen, Fenghuang Zhan, Kjartan W Egeberg, Bart Barlogie, Anders Waage, Harald Aarset, Hong Yan Dai, John D Shaughnessy, Anders Sundan, Magne Børset.
Abstract
Multiple myeloma (MM) is characterized by accumulation and dissemination of malignant plasma cells (PCs) in the bone marrow (BM). Gene expression profiling of 2 MM cell lines (OH-2 and IH-1) indicated that expression of PRL-3, a metastasis-associated tyrosine phosphatase, was induced by several mitogenic cytokines. Cytokine-driven PRL-3 expression could be shown in several myeloma cell lines at both the mRNA and protein levels. There was significantly higher expression of the PRL-3 gene in PCs from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and myeloma than in PCs from healthy persons. Among 7 MM subgroups identified by unsupervised hierarchical cluster analysis, PRL-3 gene expression was significantly higher in the 3 groups denoted as "proliferation," "low bone disease," and "MMSET/FGFR3." PRL-3 protein was detected in 18 of 20 BM biopsies from patients with MM. Silencing of the PRL-3 gene by siRNA reduced cell migration in the MM cell line INA-6, but had no detectable effect on proliferation and cell-cycle phase distribution of the cells. In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17934070 PMCID: PMC2200854 DOI: 10.1182/blood-2007-07-101139
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113